GYRE news

Gyre Therapeutics, Inc. dated October 16, 2026, agreed to employ Ying Luo as Chief Executive Officer at an annual base salary of $500,000.

Gyre Therapeutics held a corporate presentation outlining its pipeline degrader candidates, clinical development plans, and global business strategy. The company highlighted manufacturing and discovery initiatives in China.

Gyre Therapeutics posted an exhibit detailing its platform and clinical pipeline for protein degraders. The filing outlines plans to leverage China operations and specific development timelines for candidates like CG009301 and ETUARY™.

Gyre Therapeutics reported strong sales for its commercial products ETUARY and Etorel, and affirmed 2026 revenue guidance of $100.5 to $111.0 million, though net loss widened.

Gyre Therapeutics announced the appointment of CEO Yue Xiong and veterans Maxwell Kirkby and Claire Weston to its board, effective August 1, 2026. This expansion of scientific and governance expertise is intended to bolster Gyre's cross-border drug development efforts and strengthen its clinical pip…

Gyre Therapeutics filed an 8-K with a presentation outlining its fully-integrated biopharmaceutical platform combining operations with Cullgen Inc., featuring multiple product candidates across fibrosis, inflammatory and oncology indications. The filing details clinical development plans and timelin…